Marker Therapeutics (MRKR) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 1, 2026, with voting open until April 30, 2026, at 11:59 PM ET.

• Shareholders can vote online, by phone, email, or virtually attend the meeting.

• Proxy materials are available online, with options for paper or email copies upon request.

Voting matters and shareholder proposals

• Election of five directors: David Eansor, Steven Elms, Juan Vera, Katharine Knobil, and Kathryn Penkus Corzo.

• Advisory vote on executive compensation for named executive officers.

• Proposal to increase authorized common stock from 30,000,000 to 130,000,000 shares.

• Proposal to revise the voting threshold for changes to common stock.

• Ratification of CBIZ CPAS P.C. as independent auditor for fiscal year ending December 31, 2026.

• Approval to adjourn the meeting if insufficient votes are present for the share increase proposal.

Board of directors and corporate governance

• Board recommends approval for all proposals, including director nominees and amendments.